Oncology
For years, Sara worked in a hospital, making care possible for others. Now, after being diagnosed with breast cancer, she was the one in need of care.
Mwango has 16 years of drug review, development, and regulatory experience at the FDA. Before joining Parexel, she was the Associate Director for Safety in the Office of New Drugs (OND) in the Center for Drug Evaluation and Research (CDER) and was responsible for ensuring OND’s implementation of the policies and processes related to CDER safety programs, including the Safety First and Sentinel Initiatives. She has particular expertise in the development of analgesic and addiction (alcohol and opioid) therapies and post-approval activities such as pharmacovigilance, risk management, and Phase 4 studies.